UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------------------------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 30, 2003
----------------
CYTOGEN CORPORATION
--------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-14879 22-2322400
---------------------------- ------------------------ -------------------
(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation) Identification No.)
650 College Road East, CN 5308, Suite 3100, Princeton, NJ 08540
--------------------------------------------------------- ------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (609) 750-8200
--------------
ITEM 5. OTHER EVENTS.
On October 30, 2003, Matritech, Inc. and Cytogen Corporation executed an
amendment and restatement of the Distribution Agreement originally entered into
by the parties on October 18, 2002 (the "Restated Agreement"). Under the terms
of the Restated Agreement, which takes effect on November 8, 2003, Cytogen will
have a non-exclusive right to sell NMP22(R)BladderChek(TM) to urologists until
December 31, 2003 and an exclusive right to continue to sell BladderChek to
oncologists for the term of the Restated Agreement. The term of the Restated
Agreement expires on December 31, 2004 and is renewable annually thereafter upon
the mutual consent of the parties. The parties also have agreed to remove the
requirement that Cytogen sell a minimum quantity of BladderChek in order to
maintain its exclusivity.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits.
EXHIBIT NO. DESCRIPTION
----------- -----------
99.1 Press Release of Cytogen Corporation dated November
3, 2003.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this current report on Form 8-K to be signed on
its behalf by the undersigned hereunto duly authorized.
CYTOGEN CORPORATION
By: /s/ Michael D. Becker
-----------------------------------------
Michael D. Becker
President and Chief Executive Officer
Dated: November 3, 2003
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
----------- -----------
99.1 Press release of Cytogen Corporation dated November
3, 2003.